CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2028

Conditions
T-Cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Interventions
DRUG

CD5 CAR-T cells infusion

Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.

Trial Locations (3)

102200

RECRUITING

Beijing GoBroad Hospital, Beijing

200025

RECRUITING

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

200435

RECRUITING

Shanghai Liquan Hospital, Shanghai

All Listed Sponsors
collaborator

Ruijin Hospital

OTHER

collaborator

Shanghai Liquan Hospital

OTHER

lead

Beijing GoBroad Hospital

OTHER

NCT07022964 - CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas | Biotech Hunter | Biotech Hunter